Sign inJoin waitlistJoin the waitlist

MM

Michael Method

Physician · Trinity Health Grand Rapids

Credentials: · · ·

History

Trinity Health Grand Rapids
2019–Present

Gynecologic Oncology
University of Miami/Jackson Health System
1990–1993
Obstetrics and Gynecology
1986–1990
Northwestern University Feinberg School of Medicine
1982–1986

Research

A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
The Lancet Oncology · 2017 · 709 citations
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine · 2023 · 405 citations
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Journal of Clinical Oncology · 2023 · 350 citations

LK
Louis Keith
10 papers
Ursula Matulonis
7 papers
Kathleen Moore
5 papers
David O'Malley
4 papers
Michael Birrer
4 papers
RC
Robert Coleman
4 papers
Cesar Castro
3 papers
JK
Jason Konner
3 papers
Lainie Martin
3 papers
AB
Anna Berkenblit
2 papers
BS
Bernd-Uwe Sevin
2 papers
Brian Brost
2 papers · 2 as a fellow

Grants

Development of a Phenotype-Based Predictive Analytic for Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $1.3M · Vanderbilt University Medical Center
2021–2027
Northern Indiana Cancer Research Corsoortium, CCOP
National Cancer Institute · U10
Contact PI · $921K · Northern Indiana Cancer Res Consortium
2000–2015

Clinical trials

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
Principal investigator · Terminated · Phase 2
Gynecologic Oncology Group
2007
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Study director · Completed · Phase 3
ImmunoGen, Inc.
2020–2022
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012